BRAF‐V600E mutations in plasma and peripheral blood mononuclear cells correlate with prognosis of pediatric Langerhans cell histiocytosis treated with first‐line therapy

Abstract

AbstractBackgroundThe clinical relevance of BRAF‐V600E alleles in peripheral blood mononuclear cells (PBMCs) and the prognostic impact of the mutants in cell‐free (cf) and PBMC DNAs of Langerhans cell histiocytosis (LCH) have not been fully clarified in pediatric LCH.MethodsWe retrospectively determined the levels of BRAF‐V600E mutation in paired plasma and PBMC samples at the time of diagnosis of LCH. Subsequently, we performed a separate or combined analysis of the clinical and prognostic impact of the mutants.ResultsWe assessed BRAF‐V600E mutation in peripheral blood from 94 patients of childhood LCH. Our data showed that cfBRAF‐V600E was related to young age, multiple‐system (MS) disease, involvements of organs with high risk, increased risk of relapse, and worse progression‐free survival (PFS) of patients. We also observed that the presence of BRAF‐V600E in PBMCs at baseline was significantly associated with MS LCH with risk organ involvement, younger age, and disease progression or relapse. The coexisting of plasma(+)/PBMC(+) identified 36.2% of the patients with the worst outcome, and the hazard ratio was more significant than either of the two alone or neither, indicating that combined analysis of the mutation in plasma and PBMCs was more accurate to predict relapse than evaluation of either one.ConclusionsConcurrent assessment of BRAF‐V600E mutation in plasma and PBMCs significantly impacted the prognosis of children with LCH. Further prospective studies with larger cohorts need to validate the results of this study.